Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDProtalix BioTherapeutics Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$0.01 | -$0.01 | -$0.01 |
| Q2 2026 | 1 | $0.27 | $0.27 | $0.27 |
| Q3 2026 | 1 | -$0.01 | -$0.01 | -$0.01 |
| Q4 2026 | 1 | $0.01 | $0.01 | $0.01 |
| Q1 2027 | 1 | $0.01 | $0.01 | $0.01 |
| Q2 2027 | 1 | $0.01 | $0.01 | $0.01 |
| Q3 2027 | 1 | $0.04 | $0.04 | $0.04 |
| Q4 2027 | 1 | $0.08 | $0.08 | $0.08 |
Protalix BioTherapeutics Inc. Earnings Date And Information
Protalix BioTherapeutics Inc. last posted its earnings results on Wednesday, March 18th, 2026. The company reported $-0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by $0.08. The company had revenue of 9.12 M for the quarter and had revenue of 52.74 M for the year. Protalix BioTherapeutics Inc. has generated $0 earnings per share over the last year ($-0.0841 diluted earnings per share) and currently has a price-to-earnings ratio of -24.26. Protalix BioTherapeutics Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Protalix BioTherapeutics Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/18/2026 | Q4 2025 | $0.01 | -$0.07 | -0.08 | $18.30 M | $9.12 M |
| 11/13/2025 | Q3 2025 | $0.06 | $0.03 | -0.03 | $17.89 M | $17.85 M |
| 08/14/2025 | Q2 2025 | $0.03 | $0.00 | -0.03 | $15.53 M | $15.66 M |
| 05/09/2025 | Q1 2025 | $0.08 | -$0.05 | -0.13 | $21.60 M | $10.11 M |
| 03/17/2025 | Q4 2024 | $0.07 | $0.09 | 0.02 | $18.75 M | $18.22 M |
| 11/14/2024 | Q3 2024 | $0.06 | $0.04 | -0.02 | $16.26 M | $17.96 M |
| 08/14/2024 | Q2 2024 | -$0.01 | -$0.03 | -0.02 | $12.50 M | $13.47 M |
| 05/10/2024 | Q1 2024 | -$0.02 | -$0.06 | -0.04 | $9.20 M | $3.75 M |
| 03/14/2024 | Q4 2023 | -$0.03 | -$0.08 | -0.05 | N/A | $10.49 M |
| 11/06/2023 | Q3 2023 | -$0.07 | -$0.03 | 0.04 | N/A | $10.35 M |
| 08/07/2023 | Q2 2023 | $0.03 | $0.29 | 0.26 | N/A | $35.08 M |
| 05/04/2023 | Q1 2023 | N/A | -$0.05 | N/A | N/A | $9.59 M |
| 02/27/2023 | Q4 2022 | -$0.15 | -$0.07 | 0.08 | N/A | $8.62 M |
| 11/14/2022 | Q3 2022 | -$0.15 | -$0.07 | 0.08 | N/A | $14.18 M |
| 08/15/2022 | Q2 2022 | -$0.18 | -$0.11 | 0.07 | N/A | $8.75 M |
| 05/16/2022 | Q1 2022 | -$0.04 | -$0.05 | -0.01 | N/A | $16.09 M |
| 03/31/2022 | Q4 2021 | -$0.11 | -$0.15 | -0.04 | N/A | $8.55 M |
| 11/15/2021 | Q3 2021 | -$0.12 | -$0.09 | 0.03 | N/A | $12.05 M |
| 08/16/2021 | Q2 2021 | -$0.08 | -$0.25 | -0.17 | N/A | $6.43 M |
| 05/14/2021 | Q1 2021 | -$0.17 | -$0.14 | 0.03 | N/A | $11.32 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Protalix BioTherapeutics Inc. Earnings: FAQ's
The conference call for Protalix BioTherapeutics Inc.'s latest earnings report can be listened to online.
The conference call transcript for Protalix BioTherapeutics Inc.'s latest earnings report can be read online.
Protalix BioTherapeutics Inc. (:PLX) has a recorded annual revenue of $52.74 M.
Protalix BioTherapeutics Inc. (:PLX) has a recorded net income of $-6,604,000.Protalix BioTherapeutics Inc. has generated $-0.0841 earnings per share over the last four quarters.
Protalix BioTherapeutics Inc. (:PLX) has a price-to-earnings ratio of -24.26 and price/earnings-to-growth ratio is 0.08.